Is Teclistamab chemotherapy or immunotherapy?

The U.S. Food and Drug Administration(FDA)has accelerated approvalTeritusumab(Teclistamab), This is a type of immunotherapy called bispecificTcell engager(BiTE), which is used to treat adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies. Teritolumab binds to CD3 receptors expressed on the surface of T cells and BCMA expressed on the surface of MM cells and some healthy B lineage cells. Activated T cells release cytokines, causing MM cell lysis. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.